The endocannabinoid system shows promise for bladder pain but faces challenges in clinical translation

This was a narrative review of the endocannabinoid system as a therapeutic target for bladder pain, examining preclinical evidence for endocannabinoid-modulating approaches, pharmacological challenges, and emerging dual-inhibitor compounds.

Bladder pain conditions like interstitial cystitis affect millions of people and are notoriously difficult to treat. The endocannabinoid system offers a mechanistically distinct approach from opioids, potentially providing pain relief without the addiction risk and side effects that make long-term opioid use problematic for chronic bladder conditions.

This review represents part of a broader effort to harness the endocannabinoid system for pain management without using cannabis or THC directly. By boosting the body's own endocannabinoids rather than introducing exogenous cannabinoids, this approach could potentially avoid psychoactive effects while still providing pain relief through cannabinoid receptor activation.

Most evidence comes from animal models, and clinical translation of FAAH and MAGL inhibitors has been disappointing in some cases. The complex pharmacology involving multiple enzymes and receptors makes drug development challenging. The review is focused on bladder pain specifically, and findings may not apply to other pain conditions. No human clinical data on endocannabinoid modulation for bladder pain were available.